nelonicline (ABT-126) / AbbVie - LARVOL DELTA

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials. (PubMed, Acta Psychiatr Scand) - "In this comprehensive overview of clinical trials on pro-cognitive agents in schizophrenia, we identify emerging opportunities but also acknowledge a lack of replicated evidence. Despite extensive attempts to address CIAS, it remains an undertreated domain, and future trials should explore better ways to treat this important condition."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia

Recent development of piperazine and piperidine derivatives as antipsychotic agents. (PubMed, Mini Rev Med Chem) - "In this direction various antipsychotic drugs have been synthesized at laboratory level and few are under clinical trial studies such as Lu AE58054, PF-04802540, ORG25935, DMXB-A, Bitopertin and ABT-126. In the present review, we include the studies related to the effect of different substituents on piperidine/piperazine derivatives and their anti-psychotic activity. Various series of synthesized compounds by different researchers with piperidine/piperazine nucleus have been reviewed and diagrammatically represented in the form of SAR (structure activity relationships) which will help to the scientists for the development of potential lead compounds."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680) (clinicaltrials.gov) - P2; N=271; Active, not recruiting; Sponsor: AbbVie; Enrolling by invitation -> Active, not recruiting ; Trial primary completion date: Feb 2015 ->Aug 2015

Enrollment closed • Trial primary completion date • Biosimilar • Schizophrenia

Abbvie still rolls with Humira while drug pipeline develops (Forbes) - "In the next 12 to 18 months, Abbvie has seven drugs in key late-stage studies. Among them...ABT-126 for Alzheimer’s disease and schizophrenia. New data for the Alzheimer’s drug will be presented at the Alzheimer’s Association 2013 International Conference in July in Boston."

Anticipated clinical data • Alzheimer's Disease • Schizophrenia

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers. (PubMed, J Clin Psychiatry) - P2; "ABT-126 did not demonstrate a procognitive effect in subjects with stable schizophrenia who smoke. A trend for improvement in negative symptoms was observed with the high dose. The safety profile of ABT-126 was similar to placebo."

Clinical • Journal • P2b data